In 1998, the advent of trastuzumab, the first targeted anti-HER2 therapy and humanised monoclonal antibody against HER2, brought about considerable improvement in the prognosis of metastatic and early-stage HER2-positive breast cancer patients [8,9]. Here, ERBB2 is linked to breast carcinoma.